Zobrazeno 1 - 10 of 150 pro vyhledávání: '"Frank G. Haluska"'
6
Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Autor: Suzanne George, Margaret von Mehren, Jonathan A. Fletcher, Jichao Sun, Sen Zhang, Justin R. Pritchard, John Graeme Hodgson, David Kerstein, Victor M. Rivera, Frank G. Haluska, Michael C. Heinrich
Publikováno v: Clin Cancer Res
Purpose: The purpose of this study is to evaluate ponatinib for advanced gastrointestinal stromal tumors (GIST). Patients and Methods: This single-arm phase II trial enrolled patients with metastatic and/or unresectable GIST with failure of prior tyr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e46d0d6f0c0882ddcf6d04692ab7f15
https://doi.org/10.1158/1078-0432.ccr-21-2037
Zobrazit plný text záznamu
7
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Autor: Maximilian Hochmair, Sang-We Kim, Frank G. Haluska, Edward S. Kim, Luis Paz-Ares Rodríguez, Karen L. Reckamp, Howard West, Egbert F. Smit, William M. Reichmann, David Kerstein, D. Ross Camidge, Rudolf M. Huber, Scott N. Gettinger, Karin Holmskov Hansen, Natasha B. Leighl, Marcello Tiseo, Corey J. Langer, Myung-Ju Ahn, Dong Wan Kim, Harry J.M. Groen
Publikováno v: Kim, D W, Tiseo, M, Ahn, M J, Reckamp, K L, Hansen, K H, Kim, S W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Rodríguez, L G P A, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer : A randomized, multicenter phase II trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. AMER SOC CLINICAL ONCOLOGY
Kim, D-W, Tiseo, M, Ahn, M-J, Reckamp, K L, Hansen, K H, Kim, S-W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Paz-Ares Rodríguez, L G, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer : A Randomized, Multicenter Phase II Trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. American Society of Clinical Oncology
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)–rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::083080d9737f1d34cfb6ab09cbebadb2
https://research.rug.nl/en/publications/5541b9aa-c9cc-4d74-bb75-505038ae3276
Zobrazit plný text záznamu
8
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Autor: Glen J. Weiss, Rafael Rosell, Kathryn A. Gold, Meera Tugnait, Scott N. Gettinger, Timothy P. Clackson, David Kerstein, Frank G. Haluska, Lyudmila Bazhenova, Narayana I. Narasimhan, D.R. Camidge, Ravi Salgia, Corey J. Langer, Victor M. Rivera, Alice T. Shaw, David J. Dorer
Publikováno v: The Lancet Oncology. 17:1683-1696
Summary Background Anaplastic lymphoma kinase ( ALK ) gene rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC). Brigatinib (AP26113) is an investigational ALK inhibitor with potent preclinical activity against ALK mutants resis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f20cfe992a6afcba782faf4a2e9e1d
https://doi.org/10.1016/s1470-2045(16)30392-8
Zobrazit plný text záznamu
9
A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
Autor: Darren Hargrave, Sara M. Federico, Robert Iannone, Tanya M. Trippett, Steven G. DuBois, Isabelle Aerts, Frank G. Haluska, Andrew D.J. Pearson, Birgit Geoerger, Ruixue Wang, Ryan Geschwindt
Publikováno v: Oncotarget
// Andrew D.J. Pearson 1 , Sara M. Federico 2 , Isabelle Aerts 3 , Darren R. Hargrave 4 , Steven G. DuBois 5 , Robert Iannone 6 , Ryan D. Geschwindt 6 , Ruixue Wang 7 , Frank G. Haluska 8 , Tanya M. Trippett 9 , Birgit Geoerger 10 1 Paediatric Drug D
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9854f008011baf5e76acb72f6372f64d
https://doi.org/10.18632/oncotarget.12450
Zobrazit plný text záznamu
10
Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients
Autor: Michele Baccarani, Ronald Knickerbocker, David J. Dorer, Andreas Hochhaus, Moshe Talpaz, Frank G. Haluska, Jorge E. Cortes
Publikováno v: Leukemia Research. 48:84-91
Background: Ponatinib is an approved potent pan–BCR-ABL tyrosine kinase inhibitor (TKI) with proven efficacy in refractory Ph+ leukemia, particularly CP-CML. Previous analyses suggest significant association between ponatinib dose intensity and adv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355e662ac6893ef4c7d1c6c1651074bf
https://doi.org/10.1016/j.leukres.2016.07.007
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje